FDA cancer head wants advisory panels to keep voting on drugs

CHICAGO — As commissioner of the Meals and Drug Administration, Robert Califf has made clear he’d wish to put off the votes that punctuate conferences of skilled panels evaluating new medication for approval. On Sunday, Richard Pazdur, director of the FDA’s Oncology Heart of Excellence, took problem together with his boss.

It’s true that the FDA has no obligation to observe what the advisory committee recommends, however the votes assist, Pazdur stated at [email protected], STAT’s occasion on the American Society of Scientific Oncology annual assembly. “I believe we have to vote,” he stated. “We’ve to make a binary determination at FDA whether or not to or to not approve. If we’re going in a single path, and we hear a unanimous vote in opposition to — we now have to pause. It’s important to step again and say, had been we unsuitable on this?”

Califf informed STAT in an earlier dialog about advisory committees convened by the company: “I wish to do away with voting as a lot as doable. That’s a behavior. It’s not a requirement, and it’s not very helpful. I’d like extra advisory committees to be concerning the excited about the sector and the intervention that’s being assessed, not a lot the approval determination. That’s an FDA determination, not an advisory committee determination.”